Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies.

Gabriel Figueroa-ParraMichael S PutmanCynthia S CrowsonAli Duarte Garcia

Published in: Lupus science & medicine (2024)

The evidence of therapies for patients with SLE and LN is derived mostly from fragile RCTs. Clinicians and trialists must be aware of the fragility of these RCTs for clinical decision-making and designing trials for novel therapeutics.

Keyphrases

systemic lupus erythematosus
decision making
disease activity
palliative care
small molecule
rheumatoid arthritis
hip fracture